🔓
Sign in as a Member to unlock the full view of ABBV. · Full hedge fund list, every line-item carveout, cabinet conflicts, and politicians-trading detail.
Become a Member$29.99/mo already a Member? Sign in →
ABBV

AbbVie Inc.

Sector: healthcareDrug Manufacturers - GeneralNYSEMarket Cap: $397.32B

AbbVie is a large-cap pharmaceutical company whose immunology and oncology franchises are highly exposed to Medicare drug-price negotiation and FDA/patent policy.

Next filing → your inbox
Govt Dependence
82/100
Regulatory Density
90/100
Lobbying Intensity
88/100
Political Signal
HIGH

BusinessWhat ABBV does

AbbVie develops and markets branded pharmaceuticals across immunology (Skyrizi, Rinvoq, legacy Humira), oncology, neuroscience, aesthetics (Botox) and eye care. Revenue is driven by patent-protected biologics and small molecules, with heavy Medicare and commercial-payer exposure.

12 months past · 3 months futureABBV activity timeline

$304$248$191 DecJan '26FebMarAprMayJunJulAugSepOctNovDecJan '27Feb ↓ PAST — recorded activity ↑ FUTURE — scheduled markups · pending votes TODAY · Nov 17 $295.03 hi $197.38 lo $294.55 CONGRESS 30 INSIDERS 0 13F FUNDS 30 BILLS 30 Ro Khanna (D) · Purchase · 2026-10-07Pete Sessions (R) · Sale · 2026-09-14Ro Khanna (D) · Purchase · 2026-05-01Josh Gottheimer (D) · Sale · 2026-05-05Ro Khanna (D) · Purchase · 2026-01-23Ro Khanna (D) · Sale · 2026-01-29Julie Johnson (D) · Sale · 2025-12-18Julia Letlow (R) · Sale · 2025-12-08 Citadel Advisors · + $1651M · 2026-06-30Citadel Advisors · + $813M · 2026-03-31D.E. Shaw & Co. · + $616M · 2026-06-30Millennium Management · + $570M · 2026-06-30AQR Capital Management · + $507M · 2026-06-30Citadel Advisors · - $465M · 2025-12-31Millennium Management · + $365M · 2026-03-31D.E. Shaw & Co. · + $211M · 2026-03-31AQR Capital Management · OPENED $193M · 2026-03-31 MARKUP · Senate Veterans' Affairs · 2026-11-18MARKUP · Senate Finance · 2026-11-18MARKUP · Senate Health, Education, Labor, and Pensions · 2026-11-18MARKUP · Senate Budget · 2026-11-18MARKUP · Senate Veterans' Affairs · 2026-11-18
Congress
buy sell
Insider · Form 4
open-market buy
Hedge fund · 13F
opened + added − trimmed closed holds
Bills
past action (this ticker) upcoming markup (sector) ★ carveout (this ticker)
250 trading days · 8 congressional trades shown · 0 insider buys · 9 13F filings · 0 past bill actions · 5 upcoming markups

Executive Branch ConflictsABBV held by Trump-administration officials

Lifetime Government AwardsABBV federal contracts

ABBV doesn't hold direct federal contracts.

Verified via USASpending.gov: $0 reported in direct prime-contract awards. Companies in this position typically sell federal services indirectly through prime contractors and integrators (e.g., Lockheed Martin, Booz Allen, Microsoft Azure) or through commercial channels that don't appear in USASpending data.

Smart Money · 13F HoldingsHedge funds holding ABBV

$3.51B
Total ABBV held by tracked 13F funds
7
Funds with ABBV positions
Citadel Advisors $1.65B +76% 2 overlap 2026-06-30
D.E. Shaw & Co. $616M +153% 2 overlap 2026-06-30
Millennium Management $570M +35% 2 overlap 2026-06-30
AQR Capital Management $507M +127% 2 overlap 2026-06-30
Point72 Asset Management $98M +868% 2 overlap 2026-06-30
Two Sigma Investments $66M +19% 2 overlap 2026-06-30
Bridgewater Associates $3M -61% 2 overlap 2026-06-30

Politicians Trading ABBVMembers of Congress with recent ABBV positions

14 politicians traded ABBV across 87 disclosed transactions totaling $1.2M (last 730 days). Greed score = composite of trade frequency, volume & recency across the politician's entire history (not just ABBV). 0-30 LOW · 30-60 MID · 60+ HIGH.

Congressional TradesWho in Congress is trading ABBV

2026-10-07 Ro Khanna D-California · house Purchase $15,001 - $50,000
2026-09-14 Pete Sessions R-Texas · house Sale $15,001 - $50,000
2026-05-01 Ro Khanna D-California · house Purchase $15,001 - $50,000
2026-05-05 Josh Gottheimer D-New Jersey · house Sale $1,001 - $15,000
2026-01-23 Ro Khanna D-California · house Purchase $1,001 - $15,000
2026-01-29 Ro Khanna D-California · house Sale $15,001 - $50,000
2025-12-18 Julie Johnson D-Texas · house Sale $1,001 - $15,000
2024-10-23 Julia Letlow R-Louisiana · house Purchase $1,001 - $15,000 447d late
2025-01-24 Julia Letlow R-Louisiana · house Sale $1,001 - $15,000 354d late
2025-04-28 Julia Letlow R-Louisiana · house Purchase $1,001 - $15,000 260d late
2025-12-08 Julia Letlow R-Louisiana · house Sale $1,001 - $15,000
2025-11-13 Julie Johnson D-Texas · house Sale $1,001 - $15,000
30+ trades on file · most recent 2026-11-05

Corporate Insiders · Form 4What CEOs, CFOs, and directors are doing with their own stock

Stock awards & option exercises

3
option exercises · $6.7M
For ABBV, executives receive stock primarily as compensation rather than via open-market purchases — typical for established large-cap firms.

Bills Affecting ABBVLive legislation impacting this stock

Political ProfileWhere ABBV sits in Washington

bipartisan

Large-cap pharma stocks move materially on Medicare price-negotiation lists, IRA implementation, and FDA/patent policy; AbbVie's Humira/Skyrizi exposure makes it drug-pricing sensitive.

Regulatory ExposureThreats & opportunities

Regulatory threats

  • Medicare drug price negotiation expansion
  • patent thicket / biosimilar competition reform
  • FTC/FDA scrutiny of patent listings
  • IRA compulsory-licensing style proposals

Regulatory opportunities

  • FDA approval accelerations for Skyrizi/Rinvoq
  • favorable IP/tax treatment (HR.1911)
  • biosimilar market delays extending exclusivity

Capitol Hill AlliesChampions & critics

Congressional champions

  • No specific congressional champions identified.

Congressional critics

  • Sen. Warren (D-MA)
  • Sen. Sanders (I-VT)

LobbyingWho's hired to advocate for ABBV

PhRMABiotechnology Innovation Organization (BIO)U.S. Chamber of Commerce
Member intelligence layer

Live signals + predictions for ABBV — for Founders

The free page above gives you the public record. Members see the real-time intelligence layer on top of it:

Become a Founder · $29.99/mo Locked rate forever · cancel anytime

Frequently AskedAbout ABBV & political exposure

Does AbbVie Inc. (ABBV) hold federal contracts?
No direct prime contracts reported in USASpending.gov for AbbVie Inc.. Companies in the semiconductor and AI hardware sectors often sell to the federal government via prime contractors and cloud resellers (Microsoft Azure, AWS, Lockheed Martin systems integration) rather than as direct primes.
Which Trump cabinet officials own ABBV stock?
1 Trump cabinet members or senior White House staff have disclosed holdings in ABBV on their OGE 278 financial disclosures, including Donald J. Trump. See the Cabinet Conflicts panel for details.
Has Congress traded ABBV stock?
482 congressional trades by 55 unique members of Congress, most recently on 2026-10-07. See the Congressional Trading panel for politician-by-politician breakdown.
What is ABBV political risk profile?
Government dependence: 82/100. Lobbying intensity: 88/100. Political signal: high. Donor party split: bipartisan.
How does GovGreed track ABBV political activity?
GovGreed integrates STOCK Act congressional trade disclosures, FEC contributions, OGE executive-branch disclosures, USASpending federal contracts, Senate LDA lobbying filings, and SEC Form 4 corporate insider trades into a single queryable graph. ABBV data is updated daily from these official federal sources.